Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether sequential chemotherapy with capecitabine plus oxaliplatin (Xelox) followed by docetaxel plus capecitabine (TX)in unresectable gastric cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Veterans General Hospital, Taiwan
• Treatments: Capecitabine; Docetaxel; Oxaliplatin

Criteria

Inclusion Criteria:

• Pathologically confirmed gastric adenocarcinoma.

• At least one measurable lesion in a non-irradiated area.

• No prior exposure to systemic chemotherapy for advanced gastric cancer.

• For those have adjuvant chemotherapy after a curative gastrectomy, the last dosing of previous adjuvant chemotherapy should be at least 6 months before the start of this treatment.

• Aged > 20 years old.

• ECOG Performance Status <= 2.

• Life expectancy greater than 12 weeks.

• Adequate bone marrow function

• Adequate liver function

• Adequate renal function

Exclusion Criteria:

• Patient who are receiving concurrent radiotherapy, chemotherapy or other experimental therapy. (Previous radiotherapy is allowable if the last dose was given more than 1 month before the protocol treatment).

• Major surgery within two weeks prior to entering the study.

• Patients with CNS metastasis, including clinical suspicion.

• Patients who are under active or uncontrolled infections.

• Patients who had cardiac arrhythmia or myocardial infarction history 6 months before entry.

• Patients with clinically detectable peripheral neuropathy > 2 on the CTC criteria

• Patients with concomitant illness that might be aggravated by chemotherapy.

• Patients who are pregnant or with breast feeding.

• Other concomitant or previously malignancy within 5 yrs except for in situ cervix cancer or squamous cell carcinoma of the skin treated by surgery only.

• Patients with hypersensitivity to any component of the chemotherapeutic regimen.

• mental status is not fit for clinical trial

• can not take study medication orally

• fertile men and women unless using a reliable and appropriate contraceptive method